Otsuka (OTCMKTS:OTSKY) and RYTHM (NASDAQ:RYM) Head to Head Analysis

Otsuka (OTCMKTS:OTSKY) and RYTHM (NASDAQ:RYM) are both healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their analyst recommendations, dividends, earnings, profitability, valuation, institutional ownership and risk.

Risk and Volatility

Otsuka has a beta of 0.08, meaning that its share price is 92% less volatile than the S&P 500. Comparatively, RYTHM has a beta of 9.94, meaning that its share price is 894% more volatile than the S&P 500.

Insider & Institutional Ownership

6.0% of RYTHM shares are owned by institutional investors. 3.5% of RYTHM shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Otsuka and RYTHM”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Otsuka	$16.51 billion	2.51	$2.43 billion	$2.33	16.55
RYTHM	$17.28 million	1.74	-$33.26 million	($5.27)	-2.61

Otsuka has higher revenue and earnings than RYTHM. RYTHM is trading at a lower price-to-earnings ratio than Otsuka, indicating that it is currently the more affordable of the two stocks.

Analyst Recommendations

This is a summary of current ratings for Otsuka and RYTHM, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Otsuka	1	2	1	0	2.00
RYTHM	1	0	0	0	1.00

Profitability

This table compares Otsuka and RYTHM’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Otsuka	14.36%	11.90%	8.91%
RYTHM	9.84%	21.25%	5.51%

Summary

Otsuka beats RYTHM on 9 of the 13 factors compared between the two stocks.

About Otsuka

Otsuka Holdings Co., Ltd. is a Japan-based holding company whose businesses focus primarily on pharmaceuticals and nutraceuticals. Its group companies research, develop, manufacture, and market prescription medicines, consumer health products, and medical devices. Otsuka’s pharmaceutical portfolio includes treatments across areas such as mental health, kidney disease, and oncology. Its nutraceutical business offers products including Pocari Sweat and CalorieMate, alongside other nutrition and wellness products.

About RYTHM

I couldn’t verify a Nasdaq-listed company named RYTHM with the ticker RYM. If you mean Rhythm Pharmaceuticals, Inc. (NASDAQ: RYTM), it is a biopharmaceutical company developing treatments for rare genetic diseases and other conditions linked to the brain’s melanocortin-4 receptor pathway, which helps regulate hunger and body weight. Its marketed medicine, Imcivree (setmelanotide), is approved in the United States for certain forms of rare genetic obesity and acquired hypothalamic obesity. The company is based in Boston and focuses on developing and providing therapies for patients in the United States and other markets.